Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.
Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, Gooley TA, Piantadosi S, Kaup M, Ambinder RF, Huff CA, Matsui W, Bolaños-Meade J, Borrello I, Powell JD, Harrington E, Warnock S, Flowers M, Brodsky RA, Sandmaier BM, Storb RF, Jones RJ, Fuchs EJ. Luznik L, et al. Biol Blood Marrow Transplant. 2008 Jun;14(6):641-50. doi: 10.1016/j.bbmt.2008.03.005. Biol Blood Marrow Transplant. 2008. PMID: 18489989 Free PMC article. Clinical Trial.
CD34+ stem cell augmentation of elutriated allogeneic bone marrow grafts: results of a phase II clinical trial of engraftment and graft-versus-host disease prophylaxis in high-risk hematologic malignancies.
O'Donnell PV, Jones RJ, Vogelsang GB, Seber A, Ambinder RF, Flinn I, Miller C, Marcellus DC, Griffin C, Abrams R, Braine HG, Grever M, Hess AD, Piantadosi S, Noga SJ. O'Donnell PV, et al. Bone Marrow Transplant. 1998 Nov;22(10):947-55. doi: 10.1038/sj.bmt.1701476. Bone Marrow Transplant. 1998. PMID: 9849691 Clinical Trial.
Long-term results of blood and marrow transplantation for Hodgkin's lymphoma.
Akpek G, Ambinder RF, Piantadosi S, Abrams RA, Brodsky RA, Vogelsang GB, Zahurak ML, Fuller D, Miller CB, Noga SJ, Fuchs E, Flinn IW, O'Donnell P, Seifter EJ, Mann RB, Jones RJ. Akpek G, et al. J Clin Oncol. 2001 Dec 1;19(23):4314-21. doi: 10.1200/JCO.2001.19.23.4314. J Clin Oncol. 2001. PMID: 11731514
Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experience.
Smith BD, Jones RJ, Lee SM, Piantadosi S, Vala MS, Fuller D, Gore SD, Noga SJ, O'Donnell PV, Braine H, Vogelsang GB, Fuchs EJ, Flinn IW, Brodsky RA, Ambinder RF, Miller CB. Smith BD, et al. Br J Haematol. 2002 Jun;117(4):907-13. doi: 10.1046/j.1365-2141.2002.03530.x. Br J Haematol. 2002. PMID: 12060130 Free article.
Nonmyeloablative alternative donor transplants.
Luznik L, O'Donnell PV, Fuchs EJ. Luznik L, et al. Curr Opin Oncol. 2003 Mar;15(2):121-6. doi: 10.1097/00001622-200303000-00001. Curr Opin Oncol. 2003. PMID: 12601275 Review.
Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells.
Huff CA, Fuchs EJ, Noga SJ, O'Donnell PV, Ambinder RF, Diehl L, Borrello I, Vogelsang GB, Miller CB, Flinn IA, Brodsky RA, Marcellus D, Jones RJ. Huff CA, et al. Biol Blood Marrow Transplant. 2003 May;9(5):312-9. doi: 10.1016/s1083-8791(03)00075-2. Biol Blood Marrow Transplant. 2003. PMID: 12766881 Free article.
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.
Deeg HJ, Storer BE, Boeckh M, Martin PJ, McCune JS, Myerson D, Heimfeld S, Flowers ME, Anasetti C, Doney KC, Hansen JA, Kiem HP, Nash RA, O'Donnell PV, Radich JP, Sandmaier BM, Scott BL, Sorror ML, Warren EH, Witherspoon RP, Woolfrey A, Appelbaum FR, Storb R. Deeg HJ, et al. Biol Blood Marrow Transplant. 2006 May;12(5):573-84. doi: 10.1016/j.bbmt.2005.12.036. Biol Blood Marrow Transplant. 2006. PMID: 16635793 Free article. Clinical Trial.
Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes.
Warlick ED, O'Donnell PV, Borowitz M, Grupka N, Decloe L, Garrett-Mayer E, Borrello I, Brodsky R, Fuchs E, Huff CA, Luznik L, Matsui W, Ambinder R, Jones RJ, Smith BD. Warlick ED, et al. Leuk Res. 2008 Sep;32(9):1439-47. doi: 10.1016/j.leukres.2007.12.017. Epub 2008 Feb 7. Leuk Res. 2008. PMID: 18261793 Free PMC article.
116 results